Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinoma.

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD. · 2016

Read Optimized p53 immunohistochemistry is an accurate predictor of <i>TP53</i> mutation in ovarian carcinoma. by Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5091634.txt.

Introduction

Martin Köbel and eight co-authors tested a lab staining method in the Journal of Pathology: Clinical Research in 2016. Their question was whether staining for the p53 protein can stand in for gene sequencing to find mutations in TP53, a gene changed in nearly all high-grade serous ovarian cancers.

The team ran four staining assays beside gene sequencing on 171 high-grade serous tumors and 80 endometrioid tumors. The best staining method sorted tumors by mutation status with high accuracy, and after a second look at clashing cases it reached near-perfect ability to rule a mutation in or out. A stain showing normal-looking p53 still hid a mutation in a small share of cases, which caps how far the shortcut can be trusted.

Catalog record

CREATORKöbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5091634

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma By Martin Köbel, Anna M Piskorz, Sandra Lee, Shuhong Lui, Cecile LePage, Francesco Marass, Nitzan Rosenfeld, Anne‐Marie Mes Masson, James D Brenton Published in: The Journal of Pathology: Clinical Research DOI: 10.1002/cjp2.53 ABSTRACT Abstract TP53 mutations are ubiquitous in high‐grade serous ovarian carcinomas (HGSOC), and the presence of TP53 mutation discriminates between high and low‐grade serous carcinomas and is now an important biomarker for clinical trials targeting mutant p53. p53 immunohistochemistry (IHC) is widely used as a surrogate for TP53 mutation but its accuracy has not been established. The objective of this study was to test whether improved methods for p53 IHC could reliably predict TP53 mutations independently identified by next generation sequencing (NGS). Four clinical p53 IHC assays and tagged‐amplicon NGS for TP53 were performed on 171 HGSOC and 80 endometrioid carcinomas (EC). p53 expression was scored as overexpression (OE), complete absence (CA), cytoplasmic (CY) or wild type (WT). p53 IHC was evaluated as a binary classifier where any abnormal staining predicted deleterious TP53 mutation and as a ternary classifier where OE, CA or WT staining predicted gain‐of‐function (GOF or nonsynonymous), loss‐of‐function (LOF including stopgain, indel, splicing) or no detectable TP53 mutations (NDM), respectively. Deleterious TP53 mutations were detected in 169/171 (99%) HGSOC and 7/80 (8.8%) EC. The overall accuracy for the best performing IHC assay for binary and ternary prediction was 0.94 and 0.91 respectively, which improved to 0.97 (sensitivity 0.96, specificity 1.00) and 0.95 after secondary analysis of discordant cases. The sensitivity for predicting LOF mutations was lower at 0.76 because p53 IHC detected mutant p53 protein in 13 HGSOC with LOF mutations. CY staining associated with LOF was seen in 4 (2.3%) of HGSOC. Optimized p53 IHC can approach 100% specificity for the presence of TP53 mutation and its high negative predictive value is clinically useful as it can exclude the possibility of a low‐grade serous tumour. 4.1% of HGSOC cases have detectable WT staining while harboring a TP53 LOF mutation, which limits sensitivity for binary prediction of mutation to 96%. Keywords: p53, TP53, high grade serous ovarian carcinoma, endometrioid ovarian carcinoma, immunohistochemistry, prediction, biomarker, next‐generation‐sequencing INTRODUCTION High‐grade serous ovarian carcinoma (HGSOC) is the most aggressive histological type of ovarian carcinoma and pathogenic TP53 mutation is present in >96% of cases 1. TP53 mutation is frequently present in fallopian tube precursor lesions suggesting that it is an early driver event 2, 3, 4. HGSOC show remarkable intratumoural genetic heterogeneity characterized by divergent copy number abnormalities and frequent passenger substitutions – however owing to their presence in the ancestral clone, TP53 mutations are detectable in all subclones of an individual's HGSOC 5, 6, 7. The ubiquitous presence of TP53 mutations in HGSOC provides an important diagnostic feature for small tissue biopsies, particularly in distinguishing low‐grade serous carcinoma from HGSOC, and has been used for personalized disease monitoring using circulating tumour DNA in plasma samples 8, 9, 10, 11. Despite the clinical importance of TP53 mutation, rapid sequencing is not widely available and immunohistochemistry (IHC) remains the commonest method to infer TP53 mutational status. However, the accuracy of IHC as a predictor of TP53 mutation in ovarian carcinoma has not been precisely defined. Early studies showed only a modest correlation between p53 staining pattern and TP53 mutation although these results were based on limited somatic sequencing or only scored overexpression of p53 12, 13, 14, 15, 16, 17. We have previously proposed a 3‐tier scoring system to describe p53 staining in ovarian carcinoma: overexpression (OE), complete absence (CA) or wild‐type (WT) 18. OE is most commonly associated with nonsynonymous TP53 mutations, which interfere with MDM2‐induced ubiquitination and degradation of p53, resulting in excessive p53 protein accumulation in the nucleus. CA is associated with nonsense mutations, which introduce a premature stop codon that triggers nonsense‐mediated RNA decay, or indel and splice acceptor mutations that interfere with correct protein translation by introducing frame shifts or aberrant splicing. WT expression is characterized by a variable staining intensity in a variable number of tumour cell nuclei. Depending on the proliferation and maturation status of tumour cells, the number of variably intense staining nuclei can range from a few to even the majority. Interpretation with the 3‐tier pattern increases the sensitivity of IHC and abnormal p53 staining was observed in 88–94% of HGSOC as compared to 14% of endometrioid ovarian carcinoma (EC) 18, 19. However, comparison of the 3‐tier pattern to TP53 mutation in a study of 57 ovarian carcinomas showed that abnormal p53 expression predicted pathogenic mutation with a sensitivity of 94% but a specificity of only 38% 20. The functional consequences of TP53 mutations have been divided into two classes with distinct biological effects (reviewed in 21). Nonsynonymous mutations have been shown to induce gain of function (GOF) class effects including metabolic reprogramming, chromatin reorganization and increased motility and invasion 22, 23. Loss of function (LOF) class mutations, that include stopgain, frameshift and splicing mutations, have weaker tumourigenic effects than GOF mutations in genetically engineered mouse models 24, 25. Distinguishing between GOF and LOF mutations may be clinically important in HGSOC as LOF mutations have been associated with reduced overall survival 18, 26, 27. In addition, the emergence of new clinical trials testing strategies to restore wild‐type p53 conformation 28, 29, 30, 31, or to reinstate protein translation of LOF mutations 32, 33 emphasizes the need for robust and reliable IHC biomarkers for p53. The primary aim of this study was to determine the sensitivity and specificity of IHC to predict the presence and class of TP53 mutation. We compared clinically relevant assays for p53 staining to next generation sequencing of tumour tissue as the gold standard reference. The secondary aim was to investigate misclassified cases to categorize TP53 mutations with unexpected patterns of p53 staining. METHODS Study cohort and DNA extraction This study was granted ethical approval REB15‐0945. The study cohort was sourced from the Canadian Ovarian Experimental Unified Resource (COEUR) 19, 34 and the Pathology Department of Calgary Laboratory Services (CLS) 35. All cases underwent additional staining with histotype‐specific IHC as part of detailed pathological review to assign the correct ovarian histotype 19. Initial sequencing analysis was carried out on fresh‐frozen tumour tissue from the COEUR cohort and formalin‐fixed paraffin embedded (FFPE) tissue from the CLS cohort. DNA was extracted from fresh‐frozen material as previously described 34. For FFPE material, DNA was extracted from two 1 mm tissue microarray cores using the QIAam Micro DNA kit (Qiagen) following the manufacturer's protocol except that additional incubation with lysis buffer was performed at 95°C for 15 min before adding proteinase K. Tagged‐amplicon sequencing TP53 was sequenced starting with amplification of the entire coding sequence exon 2–11 of TP53 with flanking splice sites using tagged‐amplicon sequencing with the Fluidigm Access Array 48.48 platform as described previously 9. Tagged‐amplicon sequencing libraries were sequenced on the Illumina HiSeq2000 or MiSeq platforms using paired‐end 100bp reads (primer sequences available upon request). Sequencing data and variant verification were performed using an in‐house analysis pipeline and IGV software as described 9, 36. Sanger sequencing The TP53 coding sequences (exons 2–11) were amplified as described 37 with the following modifications: PCR reactions were performed in

Read the complete text